Transforming cell therapy, one cell at a time
Our investigational cell therapies are designed to replace a patient’s diseased blood and immune system with a healthy one, using precise compositions of cells to achieve balanced immune reconstitution.
Challenges of traditional treatments
While many patients receiving a conventional allogeneic or autologous graft (allograft) experience treatment success, data show its curative potential may be undermined by relapse, infection and graft versus host disease (GvHD). As a result, patients and providers are often faced with a delicate trade-off between the risk of cancer relapse, and the potential for serious treatment-related risks.
Our approach
Building a designer immune system
For illustrative purposes only. Not to scale.
Our technology
Orca Bio’s investigational high-precision cell therapies use a proprietary mix of natural immune cells and stem cells to build a new immune system. Our platform technology uses single-cell precision to create proprietary, uniquely-defined products that have the potential to transform allogeneic cell therapy.
Our products are being developed to seamlessly integrate within the current treatment system. We work with providers with the goal of delivering Orca products to patients without creating additional complexity.
Our state-of-the-art manufacturing.
Orca Bio has built its own centralized 100,000 square foot manufacturing facility to ensure consistent and reliable delivery of our high-precision cell therapies at scale, with donor to patient vein-to-vein turnaround times of 72 hours or less.
Our state-of-the-art facility represents critical infrastructure to enable the clinical advancement of our pipeline and the future commercial availability of our potentially life-saving products.
